Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹5,752 Cr
Revenue (TTM)
₹671 Cr
Net Profit (TTM)
₹175 Cr
ROE
15.7 %
ROCE
22.3 %
P/E Ratio
33
P/B Ratio
6
Industry P/E
37.59
EV/EBITDA
22
Div. Yield
0.1 %
Debt to Equity
0
Book Value
₹118.4
EPS
₹21.7
Face value
2
Shares outstanding
80,482,800
CFO
₹528.86 Cr
EBITDA
₹929.98 Cr
Net Profit
₹625.49 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Supriya Lifescience
| -3.0 | -3.8 | 5.7 | 87.9 | 23.8 | -- | -- |
|
BSE Healthcare
| -5.2 | 2.7 | 6.4 | 20.1 | 23.1 | 22.8 | 9.7 |
|
BSE Small Cap
| -6.4 | 7.0 | 11.4 | 7.0 | 24.9 | 37.4 | 16.4 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Supriya Lifescience
| 135.0 | 33.9 | -51.4 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Supriya Lifescience
|
717.4 | 5,751.7 | 670.6 | 174.5 | 34.4 | 20.3 | 33 | 6.0 |
| 707.0 | 1,977.6 | 451.8 | 50.8 | 11.4 | 16.3 | 38.9 | 6.1 | |
| 460.2 | 7,431.5 | 2,078.3 | 274.4 | 13.0 | 12.5 | 27.1 | 3.2 | |
| 385.9 | 3,829.6 | 809.8 | 82.0 | 15.4 | 14.8 | 46.7 | 6.5 | |
| 515.5 | 3,167.3 | 563.0 | -8.7 | -7.2 | -2.1 | -- | 3.8 | |
| 5,385.0 | 8,769.9 | 1,159.5 | 236.6 | 28.3 | 43.8 | 37.1 | 14.4 | |
| 714.6 | 6,887.4 | 1,247.3 | 92.0 | 16.0 | 4 | 78 | 2.9 | |
| 696.1 | 6,346.8 | 4,526.3 | 334.7 | 15.4 | 12.7 | 23.5 | 2.7 | |
| 20.0 | 1,858.4 | 466.0 | 49.4 | 10.7 | 15.1 | 37.6 | 5.4 | |
| 967.0 | 1,978.8 | 728.5 | 61.7 | 9.2 | 13.4 | 32.1 | 4.1 |
Supriya Lifescience IPO: How good is it?
5 min read•By Udhayaprakash and Karthik Anand Vijay
Supriya Lifescience IPO: Information analysis
3 min read•By Udhayaprakash and Karthik Anand Vijay
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic,... decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India. Read more
Incorporated
2008
Chairman
Satish Waman Wagh
Managing Director
Saloni Satish Wagh
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Supriya Lifescience Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Supriya Lifescience Ltd stood at ₹ 1,012 Cr as on 31-Dec-24
The share price of Supriya Lifescience Ltd is ₹717.40 (NSE) and ₹716.45 (BSE) as of 21-May-2025 10:39 IST. Supriya Lifescience Ltd has given a return of 23.79% in the last 3 years.
Supriya Lifescience Ltd has a market capitalisation of ₹ 5,752 Cr as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Supriya Lifescience Ltd is 6.04 times as on 20-May-2025, a 11% premium to its peers’ median range of 5.43 times.
The P/E ratio of Supriya Lifescience Ltd is 32.96 times as on 20-May-2025, a 12% discount to its peers’ median range of 37.59 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Supriya Lifescience Ltd and enter the required number of quantities and click on buy to purchase the shares of Supriya Lifescience Ltd.
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India.
The promoter of Supriya Lifescience Ltd is Satish Waman Wagh. Satish Waman Wagh owns 67.64 per cent of the total equity. The chairman of the company is Satish Waman Wagh , and the managing director is Saloni Satish Wagh..
There is no promoter pledging in Supriya Lifescience Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,615
|
|
|
7,186
|
|
|
6,919
|
|
|
6,098
|
|
|
3,812
|
|
|
3,269
|
|
|
2,030
|
|
|
2,006
|
|
|
1,646
|
| Supriya Lifescience Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
20.28
|
|
Operating margin(%)
|
34.37
|
|
Net Margin(%)
|
25.68
|
|
Dividend yield(%)
|
0.11
|
Yes, TTM profit after tax of Supriya Lifescience Ltd was ₹175 Cr.
₹2.60
(
